Literature DB >> 8958449

Signal transduction pathways modulated by the D2 subfamily of dopamine receptors.

R M Huff1.   

Abstract

The D2 subfamily of dopamine receptors includes D2A, D2B, D3, and D4 dopamine receptors. These receptors activate cellular effector systems, principally through pertussis toxin-sensitive G-proteins. Historically, D2-like receptors in brain tissues were recognized as the dopamine receptor subtypes that inhibit adenylyl cyclase. Recent studies, reviewed here, have shown that multiple effector systems can be activated by these receptors, and the potential involvement of these in dopaminergic neutrotransmission is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958449     DOI: 10.1016/s0898-6568(96)00074-5

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  16 in total

1.  Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo.

Authors:  G L Snyder; P B Allen; A A Fienberg; C G Valle; R L Huganir; A C Nairn; P Greengard
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

2.  Most central nervous system D2 dopamine receptors are coupled to their effectors by Go.

Authors:  M Jiang; K Spicher; G Boulay; Y Wang; L Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 3.  Dopamine receptor localization in the mammalian retina.

Authors:  J Nguyen-Legros; C Versaux-Botteri; P Vernier
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

4.  Iron-dextran injection into the substantia nigra in rats decreases striatal dopamine content ipsilateral to the injury site and impairs motor function.

Authors:  Antonio Bueno-Nava; Rigoberto Gonzalez-Pina; Alfonso Alfaro-Rodriguez
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

Review 5.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

6.  Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.

Authors:  Lindsay R Riddle; Rakesh Kumar; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2010-09-17       Impact factor: 5.250

Review 7.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 8.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012

9.  Dopamine agonist signalling in the hypothalamus of female rats is independent of calcium-dependent kinases.

Authors:  B Balasubramanian; S K Mani
Journal:  J Neuroendocrinol       Date:  2009-09-01       Impact factor: 3.627

10.  Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling.

Authors:  Jessica L Smith; David A Stein; David Shum; Matthew A Fischer; Constantin Radu; Bhavneet Bhinder; Hakim Djaballah; Jay A Nelson; Klaus Früh; Alec J Hirsch
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.